Guarding U.S. Medicare Against Rising Drug Costs Model (GUARD)

Analysis updated November 9, 2026

Strategic questions for your team

Which drugs in our current Part D formulary or specialty pharmacy pipeline fall within the 17 GUARD-covered therapeutic categories (including antineoplastics, immunological agents, blood glucose regulators, and cardiovascular agents), and what share of our organization's Part D-aligned patient population relies on sole-source drugs or sole-source biologics that would be subject to the new international benchmark rebate calculation starting January 1, 2027?
Given that GUARD operates in randomly selected geographic areas representing 25% of Medicare Part D enrollees, have we determined whether our primary service areas fall within the selected geographies — and if so, what is the projected financial impact on patient out-of-pocket costs, medication adherence rates, and downstream utilization (e.g., ED visits, hospitalizations) that our CFO and CMO should model before the model launches?
Since GUARD's rebate benchmark will be derived from international pricing in countries meeting specific GDP per capita and minimum real economy size thresholds — rather than the current domestic benchmark — how will our pharmacy contracting, formulary management, and PBM relationships need to be restructured to account for the potential net price reductions on high-cost Part D drugs between 2027 and 2031, with reconciliation extending through 2033?
What is our organization's current exposure to the 17 covered therapeutic categories in terms of specialty drug spend, and have we stress-tested our financial projections against the scenario where manufacturer rebates to the Medicare SMI Trust Fund reduce net drug costs materially — potentially affecting our ACO or value-based contract savings calculations if patients shift toward previously unaffordable therapies and increase utilization volume?
Since GUARD is explicitly a mandatory model targeting drug manufacturers — not providers — and therefore does NOT qualify as an Advanced APM or MIPS APM under the Quality Payment Program, how does this affect our physician group's and ACO's QPP strategy, and should we prioritize other CMMI models that carry APM designation to meet MIPS exemption thresholds before the 2027 launch?
Given that the NPRM comment deadline was February 23, 2026, and the model is scheduled to launch January 1, 2027, has our organization engaged legal, regulatory, or trade association resources to monitor whether the final rule modifies the international benchmark methodology, the list of eligible therapeutic categories, or the 25% geographic coverage scope — any of which could materially change our patient population's access to affected drugs?
How should our CMO and care management teams prepare for the clinical scenario in which GUARD successfully reduces out-of-pocket costs for patients on sole-source drugs in categories like antineoplastics, antivirals, or genetic/enzyme disorder treatments — driving increased adherence and potentially higher chronic care management volume — and what staffing, care coordination, and technology investments are needed to absorb that demand by 2027?
Considering that Part D gross drug spending grew from $121 billion in 2014 to $276 billion in 2023 (approximately 10% annually) and represented ~30% of overall U.S. gross drug spending in 2024, what is our health system's or MA plan's strategic positioning if GUARD achieves meaningful Part D cost reduction — and does this create a competitive opportunity to enhance Part D benefit design, adjust bid strategy, or differentiate on medication access for the 2027-2031 performance period?

Traps and concerns

International Benchmark Data Integrity Gap
GUARD's rebate calculation hinges on a benchmark derived from 'manufacturer-reported international pricing information or available information to CMS' for countries meeting GDP per capita and minimum real economy size thresholds. This dual-track data sourcing creates a verification asymmetry: manufacturers have strong financial incentives to report international net prices (after confidential rebates and discounts common in European reference pricing systems) rather than list prices, potentially inflating the benchmark and shrinking their rebate liability. CMS has no established infrastructure to independently audit foreign net transaction prices, and most comparator countries use opaque confidential rebate agreements with their own national payers. If the benchmark is systematically overstated by even 10-15%, the savings projection against a $276 billion 2023 Part D gross spend baseline could be materially eroded. Manufacturers should expect disputes over country selection and price verification methodology to be a primary litigation vector post-final rule.
Geographic Randomization Creates Coverage Arbitrage Risk
GUARD applies only in randomly selected geographic areas representing 25% of Medicare Part D enrollees, leaving 75% of the market operating under the existing domestic inflation rebate benchmark. This structural asymmetry creates a commercially exploitable boundary: Part D plan sponsors, PBMs, and potentially beneficiaries in non-GUARD geographies face no model-driven price pressure, and manufacturers subject to GUARD rebates in the 25% zone cannot legally or practically price-discriminate by geography within the U.S. market. The more significant risk is legal challenge: manufacturers may argue the mandatory, geographically variable rebate obligation violates uniformity requirements or constitutes an unlawful taking, particularly for sole-source drugs with no competitive alternatives. Plan sponsors operating in GUARD zones must also assess whether their formulary and bid strategies for 2027 plan year submissions accurately model rebate offsets flowing to the Trust Fund rather than to plan economics.
Rebate Reconciliation Tail Extends to 2033
The model's 5-year performance period runs January 1, 2027 through December 31, 2031, but rebate invoicing and reconciliation explicitly continues into 2033 — a 2-year tail beyond model close. This extended reconciliation window creates multi-year contingent liability on manufacturer balance sheets that must be accrued under GAAP, potentially triggering material disclosure obligations for publicly traded pharmaceutical companies. For CMS and participating plan sponsors, the 2033 tail means audit risk, dispute resolution, and cash-flow uncertainty persist well after the model nominally ends. Historical experience with Part D reconciliation processes — including the existing inflation rebate program — shows that invoice disputes, data corrections, and coverage determinations can extend timelines further than planned. Manufacturers and finance teams should model worst-case scenarios where rebate invoices arrive in 2032-2033 for drug years dating to 2027, requiring retention of pricing records and contract documentation for a minimum 6-year lookback.
Sole-Source Drug Classification Dispute Risk
GUARD explicitly targets 'sole-source drugs and sole-source biologics' within 17 named therapeutic categories spanning analgesics through respiratory agents. The classification of a drug as sole-source — meaning no therapeutically equivalent competitor — is both legally contestable and dynamically unstable over a 5-year model period. A drug classified as sole-source at model launch in January 2027 may face biosimilar entry or generic approval by 2028 or 2029, altering its rebate eligibility mid-model with no clear transition mechanism described in the NPRM. Conversely, manufacturers may strategically pursue patent extensions, authorized generics, or minor reformulations to argue a product no longer meets sole-source criteria. Each reclassification event triggers retroactive rebate recalculation risk and administrative burden for both CMS and manufacturers. Given that the 17 included therapeutic categories encompass antineoplastics, immunological agents, and genetic/enzyme disorder treatments — categories with active biosimilar pipelines — this is a high-probability operational disruption rather than a tail risk.
Mandatory Model Exposure Without Provider Levers
Unlike CMMI models that include provider participants with shared savings or quality incentives, GUARD explicitly confirms that 'health care providers would not be participants in the model' and does not qualify as an Advanced APM or MIPS APM. Manufacturers are the sole participants subject to mandatory rebate obligations. This design means ACOs, hospital systems, integrated delivery networks, and Medicare Advantage plans operating in GUARD geographies have no formal mechanism to influence model execution, receive model-related payments, or protect themselves from downstream formulary or access disruptions that may result from manufacturer responses to rebate pressure. If manufacturers facing rebate liability respond by limiting distribution, withdrawing products from Part D formularies, or prioritizing commercial channel volume over Medicare, providers bear the patient care consequences — delayed access, therapeutic substitution, or gaps in specialty drug availability — without any model-based remediation pathway or financial offset.
Legal Challenge Probability Under Current Administration
GUARD is proposed under Section 1115A of the Social Security Act, which authorizes CMMI to test payment and service delivery models. The NPRM comment period closed February 23, 2026, with the Trump administration — under CMS Administrator Dr. Mehmet Oz and CMMI Director Abe Sutton — having inherited and advanced this rulemaking. Pharmaceutical manufacturers are highly likely to challenge a final rule on at least three grounds: (1) whether mandatory rebate modification falls within CMMI's Section 1115A authority versus requiring separate statutory authorization, given recent Supreme Court skepticism of broad agency rulemaking under the major questions doctrine; (2) whether using international reference pricing constitutes a form of price control Congress did not authorize; and (3) Fifth Amendment takings claims for sole-source biologics with limited ability to exit the Medicare market. A successful preliminary injunction before January 1, 2027 launch would strand CMS implementation investments and disrupt plan sponsor bid calculations already submitted for the 2027 plan year. Organizations should not build strategic plans around 2027 GUARD savings without probability-weighting a 12-24 month litigation delay scenario.
Part D Plan Bid and Premium Modeling Uncertainty
GUARD operates through manufacturer rebates paid directly to the Medicare Supplementary Medical Insurance Trust Fund — not to Part D plan sponsors. This pass-through structure means the financial benefit flows to the government, not to plan economics, complicating how Part D sponsors in the 25% GUARD geography model their 2027 bids. Plan sponsors must estimate drug costs for actuarial bid submissions without certainty about which drugs will be subject to GUARD rebates, what the international benchmarks will be set at, or whether manufacturers will respond to rebate exposure by altering list prices, formulary placement, or prior authorization requirements before the benefit year begins. The 17 therapeutic categories covered are among the highest-cost Part D segments — antineoplastics, immunologics, and cardiovascular agents alone represent disproportionate shares of the $276 billion 2023 gross spend. Actuarial mispricing in GUARD geographies could result in plan sponsors either overpricing premiums relative to actual net costs (losing enrollment) or underpricing if GUARD rebates are delayed or disputed, creating solvency pressure against CMS reconciliation timelines extending to 2033.